Latest stock research reports with share price targets forecast, buy, hold, and sell recommendations along with upside. Search by company or broker name.
Suzlon began FY26 on a strong note, with higher capacity utilization driving improved margins in the wind turbine segment. Backed by a robust 5.7 GW order book, we project a 42% CAGR in revenue over FY2527E, supported by management's guidance and strong delivery momentum. Enhanced utilization is expected to unlock volume leverage, leading to a 117 bps margin expansion, primarily from the WTG and forging businesses. With...
Strong focus on scaling up construction chemical business: Company targets to scale this construction chemicals business revenue to Rs 2000 crore in the next 4-5 years (from Rs 210 crore revenue in FY25), with revenue share increasing to 12.5% by FY30E (from 2.5% in FY25), led by healthy demand in...
Management retained its guidance of mid-single digit MHCV volume growth and slightly higher growth in the LCV segment for FY26E, led by a stronger 2HFY26E driven by replacement demand, higher government capex, easing steel costs, and new product launches across MHCV, LCV, and alternate fuel platforms.
*over or under performance to benchmark index PB Fintech Ltd (PBFL) owns online financial services platformPolicyBazaar. By collaborating with financial services companies, including insurance providers, the company aims to enrich its platform and deliver a seamless consumer experience...
JSWINFRA’s strategy of augmenting capacity, modernizing infrastructure, and pursuing selective acquisitions is well aligned with India’s long-term port sector growth ambitions, as the government targets a fourfold expansion of capacity to 10,000MTPA by FY47 from the current ~2,700MTPA.
KPIT remains optimistic about its AI-driven mobility capabilities and ongoing solution development. A strong deal pipeline and significant wins over the past two quarters are expected to drive revenue growth. The company continues to enhance efficiency and margins through AI-led productivity, fixed-price models, and cost optimization. Increased client engagement is anticipated in H2FY26, supported by new vehicle programs in...
Glenmark Pharmaceuticals’ (Glenmark) Q1FY26 performance was below our expectation due to muted show across regions. Rise in other operating income inflated margins and PAT.
The company aims to enhance capacity utilization through backward integration, with the launch of new products is expected to strengthen its near-term revenue outlook. New segments such as drones and retail, along with stabilized raw material prices and operational improvements, are likely to support profitability going forward. Accordingly, we revise our rating on the stock to ACCUMULATE, with a revised...
